Bispecific Antibodies for Cancer Therapy: A New Class of Immunotherapy

For decades, cancer treatment has relied on conventional methods such as surgery, chemotherapy, and radiotherapy. However, immunotherapy, which activates the body’s own immune system to destroy cancer cells, has brought about a revolutionary shift in recent years. Within this domain, bispecific antibodies (BsAbs) have emerged as a novel and effective class.

What are Bispecific Antibodies?

  • Bispecific antibodies are specially engineered laboratory-made antibodies that can simultaneously recognize and bind to two different antigens or cell types.
  • In cancer immunotherapy, their primary goal is to create a “molecular bridge” between immune cells (like T-cells) and cancer cells, enabling immune cells to directly ....
Do You Want to Read More?
Subscribe Now

To get access to detailed content

Already a Member? Login here


Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.

Related Content